celecoxib has been researched along with Intestinal Polyps in 9 studies
Intestinal Polyps: Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although celecoxib reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of cardiovascular events and alternatives need to be explored." | 2.78 | Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. ( Dees, J; Dekker, E; Kampman, E; Koornstra, JJ; Langers, AM; Mathus-Vliegen, EM; Nagengast, FM; Nagtegaal, ID; Peters, WH; Roelofs, HM; van Heumen, BW; Vink-Börger, ME, 2013) |
| "Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice." | 1.43 | Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden. ( Benezra, R; Dannenberg, AJ; Gross, SS; Karoly, ED; Leve, ND; Ling, L; McNally, EM; Montrose, DC; Pamer, EG; Sue, E; Suen, CS; Yantiss, RK; Zhou, XK, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Heumen, BW | 1 |
| Roelofs, HM | 1 |
| Vink-Börger, ME | 1 |
| Dekker, E | 1 |
| Mathus-Vliegen, EM | 1 |
| Dees, J | 1 |
| Koornstra, JJ | 1 |
| Langers, AM | 1 |
| Nagtegaal, ID | 1 |
| Kampman, E | 1 |
| Peters, WH | 1 |
| Nagengast, FM | 1 |
| Montrose, DC | 1 |
| Zhou, XK | 1 |
| McNally, EM | 1 |
| Sue, E | 1 |
| Yantiss, RK | 1 |
| Gross, SS | 1 |
| Leve, ND | 1 |
| Karoly, ED | 1 |
| Suen, CS | 1 |
| Ling, L | 1 |
| Benezra, R | 1 |
| Pamer, EG | 1 |
| Dannenberg, AJ | 1 |
| Ignatenko, NA | 1 |
| Besselsen, DG | 1 |
| Stringer, DE | 1 |
| Blohm-Mangone, KA | 1 |
| Cui, H | 1 |
| Gerner, EW | 1 |
| Cho, NL | 1 |
| Redston, M | 1 |
| Zauber, AG | 1 |
| Carothers, AM | 1 |
| Hornick, J | 1 |
| Wilton, A | 1 |
| Sontag, S | 1 |
| Nishioka, N | 1 |
| Giardiello, FM | 1 |
| Saltzman, JR | 1 |
| Gostout, C | 1 |
| Eagle, CJ | 1 |
| Hawk, ET | 1 |
| Bertagnolli, MM | 1 |
| Iguchi, G | 1 |
| Chrysovergis, K | 1 |
| Lee, SH | 1 |
| Baek, SJ | 1 |
| Langenbach, R | 1 |
| Eling, TE | 1 |
| Couzin, J | 1 |
| Buchanan, FG | 1 |
| Holla, V | 1 |
| Katkuri, S | 1 |
| Matta, P | 1 |
| DuBois, RN | 1 |
| Beitz, J | 1 |
| Phillips, RK | 1 |
| Wallace, MH | 1 |
| Lynch, PM | 1 |
| Hawk, E | 1 |
| Gordon, GB | 1 |
| Saunders, BP | 1 |
| Wakabayashi, N | 1 |
| Shen, Y | 1 |
| Zimmerman, S | 1 |
| Godio, L | 1 |
| Rodrigues-Bigas, M | 1 |
| Su, LK | 1 |
| Sherman, J | 1 |
| Kelloff, G | 1 |
| Levin, B | 1 |
| Steinbach, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)[NCT00808743] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for celecoxib and Intestinal Polyps
| Article | Year |
|---|---|
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Celecoxib; Cholagogues and Choleretics; Cycloox | 2013 |
Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Biomarkers; Celecoxib; C | 2008 |
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; C | 2002 |
6 other studies available for celecoxib and Intestinal Polyps
| Article | Year |
|---|---|
Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Feces; Gastrointestinal Microbi | 2016 |
Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Biogenic Polyamines; Celecoxib; Chemoprevention; Eflor | 2008 |
A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2.
Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Gene Expression Regulation | 2009 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ce | 2007 |
Trial endpoints for drug approval in oncology: Chemoprevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Female; Humans; Intestinal Polyps; Investigati | 2001 |